Personalized cancer vaccines: Targeting the cancer mutanome

Vaccine

Volumn 35, Issue 7, 2017, Pages 1094-1100

  Zhang, Xiuli ^a   Sharma, Piyush K ^a   Peter Goedegebuure, S ^a,b   Gillanders, William E ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Washington University in St Louis School of Medicine   (United States)

Author keywords

Cancer vaccine; Genome sequencing; Neoantigen; Personalized

Indexed keywords

CANCER VACCINE; DNA VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; TUMOR ANTIGEN;

ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; DRUG IDENTIFICATION; DRUG TARGETING; HUMAN; MALIGNANT NEOPLASM; NEXT GENERATION SEQUENCING; NONHUMAN; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ANTIGEN PRESENTATION; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; CHEMISTRY; CLINICAL TRIAL (TOPIC); DEVICES; DRUG EFFECTS; GENE VECTOR; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASM; PATHOLOGY; PROCEDURES; SYNTHESIS;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; GENETIC VECTORS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PEPTIDES; PRECISION MEDICINE; RECEPTORS, ANTIGEN, T-CELL; VACCINES, DNA;

EID: 84979496951     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.05.073     Document Type: Article

References (54)

1. [1] Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:6832 (2001), 1107–1111.
2. [2] Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J., Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29 (2011), 235–271.
3. [3] Dighe, A.S., Richards, E., Old, L.J., Schreiber, R.D., Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1:6 (1994), 447–456.
4. [4] Schreiber, R.D., Old, L.J., Smyth, M.J., Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:6024 (2011), 1565–1570.
5. [5] Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95:13 (1998), 7556–7561.
6. [6] DuPage, M., Mazumdar, C., Schmidt, L.M., Cheung, A.F., Jacks, T., Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482:7385 (2012), 405–409.
7. [7] van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:5038 (1991), 1643–1647.
8. [8] Parmiani, G., De Filippo, A., Novellino, L., Castelli, C., Unique human tumor antigens: immunobiology and use in clinical trials. J Immunol 178:4 (2007), 1975–1979.
9. [9] Li, L., Goedegebuure, P., Mardis, E.R., Ellis, M.J., Zhang, X., Herndon, J.M., et al. Cancer genome sequencing and its implications for personalized cancer vaccines. Cancers (Basel) 3:4 (2011), 4191–4211.
10. [10] Ley, T.J., Mardis, E.R., Ding, L., Fulton, B., McLellan, M.D., Chen, K., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456:7218 (2008), 66–72.
11. [11] Ding, L., Ellis, M.J., Li, S., Larson, D.E., Chen, K., Wallis, J.W., et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:7291 (2010), 999–1005.
12. [12] Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:7457 (2013), 214–218.
13. [13] Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., et al. Signatures of mutational processes in human cancer. Nature 500:7463 (2013), 415–421.
14. [14] Cancer Genome Atlas, N: Comprehensive molecular portraits of human breast tumours. Nature 490:7418 (2012), 61–70.
15. [15] Biankin, A.V., Waddell, N., Kassahn, K.S., Gingras, M.C., Muthuswamy, L.B., Johns, A.L., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:7424 (2012), 399–405.
16. [16] NCI Prepares to Launch MATCH Trial. Cancer Discov; 2015.
17. [17] Sjoblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314:5797 (2006), 268–274.
18. [18] Srivastava, N., Srivastava, P.K., Modeling the repertoire of true tumor-specific MHC I epitopes in a human tumor. PLoS ONE, 4(7), 2009, e6094.
19. [19] Segal, N.H., Parsons, D.W., Peggs, K.S., Velculescu, V., Kinzler, K.W., Vogelstein, B., et al. Epitope landscape in breast and colorectal cancer. Cancer Res 68:3 (2008), 889–892.
20. [20] Sensi, M., Anichini, A., Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Clin Cancer Res 12:17 (2006), 5023–5032.
21. [21] Carbone, D.P., Ciernik, I.F., Kelley, M.J., Smith, M.C., Nadaf, S., Kavanaugh, D., et al. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol 23:22 (2005), 5099–5107.
22. [22] Parker, K.C., Bednarek, M.A., Coligan, J.E., Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:1 (1994), 163–175.
23. [23] van Buuren, M.M., Calis, J.J., Schumacher, T.N., High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. Oncoimmunology, 3, 2014, e28836.
24. [24] Angell, T.E., Lechner, M.G., Jang, J.K., LoPresti, J.S., Epstein, A.L., MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 20:23 (2014), 6034–6044.
25. [25] del Campo, A.B., Carretero, J., Aptsiauri, N., Garrido, F., Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens 79:3 (2012), 147–154.
26. [26] Campoli, M., Ferrone, S., HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol 33:4 (2011), 321–334.
27. [27] Matsushita, H., Vesely, M.D., Koboldt, D.C., Rickert, C.G., Uppaluri, R., Magrini, V.J., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482:7385 (2012), 400–404.
28. [28] Castle, J.C., Kreiter, S., Diekmann, J., Lower, M., van de Roemer, N., de Graaf, J., et al. Exploiting the mutanome for tumor vaccination. Cancer Res 72:5 (2012), 1081–1091.
29. [29] van Rooij, N., van Buuren, M.M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 31:32 (2013), e439–e442.
30. [30] Robbins, P.F., Lu, Y.C., El-Gamil, M., Li, Y.F., Gross, C., Gartner, J., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 19:6 (2013), 747–752.
31. [31] Kreiter, S., Castle, J.C., Tureci, O., Sahin, U., Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology 1:5 (2012), 768–769.
32. [32] Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515:7528 (2014), 577–581.
33. [33] Yadav, M., Jhunjhunwala, S., Phung, Q.T., Lupardus, P., Tanguay, J., Bumbaca, S., et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515:7528 (2014), 572–576.
34. [34] Baxevanis, C.N., Papamichail, M., Perez, S.A., Prostate cancer vaccines: the long road to clinical application. Cancer Immunol Immunother 64:4 (2015), 401–408.
35. [35] Vanderlugt, C.L., Miller, S.D., Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2:2 (2002), 85–95.
36. [36] Liu, M.A., DNA vaccines: an historical perspective and view to the future. Immunol Rev 239:1 (2011), 62–84.
37. [37] Peoples, G.E., Holmes, J.P., Hueman, M.T., Mittendorf, E.A., Amin, A., Khoo, S., et al. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 14:3 (2008), 797–803.
38. [38] Yamada, A., Sasada, T., Noguchi, M., Itoh, K., Next-generation peptide vaccines for advanced cancer. Cancer Sci 104:1 (2013), 15–21.
39. [39] Melief, C.J., van der Burg, S.H., Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8:5 (2008), 351–360.
40. [40] Bijker, M.S., van den Eeden, S.J., Franken, K.L., Melief, C.J., van der Burg, S.H., Offringa, R., Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol 38:4 (2008), 1033–1042.
41. [41] Sabbatini, P., Tsuji, T., Ferran, L., Ritter, E., Sedrak, C., Tuballes, K., et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res 18:23 (2012), 6497–6508.
42. [42] Tsuji, T., Sabbatini, P., Jungbluth, A.A., Ritter, E., Pan, L., Ritter, G., et al. Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 1:5 (2013), 340–350.
43. [43] Rapoport, A.P., Aqui, N.A., Stadtmauer, E.A., Vogl, D.T., Xu, Y.Y., Kalos, M., et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res 20:5 (2014), 1355–1365.
44. [44] Carreno, B.M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A.A., et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science, 2015.
45. [45] Wolchok, J.D., Hodi, F.S., Weber, J.S., Allison, J.P., Urba, W.J., Robert, C., et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 1291 (2013), 1–13.
46. [46] Shin, D.S., Ribas, A., The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. Curr Opin Immunol 33 (2015), 23–35.
47. [47] Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med, 6(254), 2014 254ra128.
48. [48] Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science(6230), 2015, 124–128.
49. [49] Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:7528 (2014), 568–571.
50. [50] Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:7528 (2014), 563–567.
51. [51] Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:7528 (2014), 558–562.
52. [52] Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161:2 (2015), 205–214.
53. [53] Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348:6230 (2015), 56–61.
54. [54] Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1 (2013), 1–10.